Original contributionReduced N-acetylaspartate content in the frontal part of the brain in patients with probable Alzheimer's disease
References (25)
- et al.
N-acetyl aspartate acid: A literature review of a compound prominent in 1H-NMR spectroscopic studies of the brain
Neurosci. Biobehav. Rev.
(1989) - et al.
In vivo quantification of brain metabolites by 1H-MRS using water as an internal standard
Magn. Reson. Imaging
(1993) - et al.
“Mini-Mental State.” A practical method for grading cognitive state of patients for the clinician
J. Psychiatr. Res.
(1975) - et al.
The concentration of N-acetyl aspartate, creatine + phosphocreatine, and choline in different parts of the brain in adulthood and senium
Magn. Reson. Imaging.
(1993) - et al.
Proton MR spectroscopy of the brain with dementia
- et al.
Localized in vivo proton NMR study of Alzheimer's disease: Initial findings
- et al.
Regional correlation of N-acetyl-l-aspartic acid concentration with severity of dementia in Alzheimer's disease
- et al.
Cerebral metabolic alterations in normal aging and alzheimer's dementia detected by proton magnetic resonance spectroscopy
- et al.
In vivo abnormalities of cerebral Myo-Inositol and N-acetyl (NA) residues in Alzheimer disease (AD)
- et al.
Some investigations of senile dementia of Alzheimer type (SDAT) by 1H-CSI
Effects of normal aging and Alzheimer's disease on cerebral 1H metabolites
Single volume proton spectroscopy in Alzheimer's disease patients: A multicenter pilot study
Cited by (44)
Meta-analysis and open-source database for in vivo brain Magnetic Resonance spectroscopy in health and disease
2023, Analytical BiochemistryLower brain and blood nutrient status in Alzhiemer's disease: Results from meta-analyses
2017, Alzheimer's and Dementia: Translational Research and Clinical InterventionsChapter 6 Proton Magnetic Resonance Spectroscopy In Dementias And Mild Cognitive Impairment
2009, International Review of NeurobiologyCitation Excerpt :Thus, the presence and pattern of cortical metabolic abnormalities are of potential clinical value in identifying the underlying neuropathology of AD and discriminating this disease from other dementias (Kantarci et al., 2008). Reduction in NAA is the most frequent 1H MRS finding in AD (Adalsteinsson et al., 2000; Chantal et al., 2002; Christiansen et al., 1995; Ernst et al., 1997; Heun et al., 1997; Parnetti et al., 1997; Rose et al., 1999; Schuff et al., 1997; Watanabe et al., 2002). Single voxel 1H MRS studies of AD have consistently found reductions in NAA/Cr in the hippocampus/medial temporal lobe (Chantal et al., 2002, 2004; Dixon et al., 2002; Jessen et al., 2000; Schuff et al., 1997; Watanabe et al., 2002) and other temporal lobe regions (Frederick et al., 1997; Herminghaus et al., 2003; Kantarci et al., 2000; Parnetti et al., 1997), and the midline parietal lobe/posterior cingulate (Antuono et al., 2001; Griffith et al., 2007a; Hattori et al., 2002; Herminghaus et al., 2003; Kantarci et al., 2000, 2002b, 2003; Martinez‐Bisbal et al., 2004; Rose et al., 1999), although two studies have failed to find abnormal NAA measures in this latter region (Waldman and Rai, 2003; Watanabe et al., 2002).
Chapter 15 Advances in Neuroimaging
2007, Blue Books of NeurologyA review of <sup>1</sup>H MR spectroscopy findings in Alzheimer's disease
2005, Neuroimaging Clinics of North AmericaIn vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease
2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry